Quick Answer
Avalo Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $15.86 million for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -88.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $15.73 million | Q1 2015: $8.66 million | Q2 2015: $6.14 million | Q3 2015: $3.31 million | Q1 2016: $16.60 million | Q2 2016: $11.88 million | Q3 2016: $8.82 million | Q1 2017: $3.00 million | Q2 2017: $5.46 million | Q3 2017: $23.96 million | Q1 2018: $2.52 million | Q2 2018: $2.18 million | Q3 2018: $6.84 million | Q1 2019: $16.12 million | Q2 2019: $9.39 million | Q3 2019: $5.25 million | Q1 2020: $5.66 million | Q2 2020: $45.39 million | Q3 2020: $33.39 million | Q1 2021: $38.29 million | Q2 2021: $40.44 million | Q3 2021: $71.51 million | Q1 2022: $38.47 million | Q2 2022: $11.25 million | Q3 2022: $16.94 million | Q1 2023: $16.69 million | Q2 2023: $6.31 million | Q3 2023: $10.18 million | Q1 2024: $110.18 million | Q2 2024: $93.43 million | Q3 2024: $81.86 million | Q1 2025: $125.05 million | Q2 2025: $42.29 million | Q3 2025: $26.96 million.
- Over the full 14 years of available data (2012 to 2025), Avalo Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 66.6%.
- Historical annual values: Fiscal year 2025: $15.86 million | Fiscal year 2024: $134.55 million | Fiscal year 2023: $7.42 million | Fiscal year 2022: $13.17 million | Fiscal year 2021: $54.59 million | Fiscal year 2020: $18.92 million | Fiscal year 2019: $3.61 million | Fiscal year 2018: $10.65 million | Fiscal year 2017: $2.47 million | Fiscal year 2016: $5.13 million | Fiscal year 2015: $21.16 million | Fiscal year 2014: $11.74 million | Fiscal year 2013: $3.42 million | Fiscal year 2012: $9.52 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: